• Explore /
  • Poster
  • / A phase 2 study of berzosertib (M6620) in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.

A phase 2 study of berzosertib (M6620) in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.

Abstract Video & Slides Poster

Authors

null

Atish Dipankar Choudhury

Dana-Farber Cancer Institute, Boston, MA

Atish Dipankar Choudhury , Wanling Xie , Edmund Folefac , Daniel Lee , Mamta Parikh , David Johnson Einstein , Elizabeth R Kessler , Tina M. Mayer , Rana R. McKay , Amanda Fredericks Pace , Bose Kochupurakkal , Kent William Mouw , Eliezer Mendel Van Allen , Charles Kunos , Alan D. D'Andrea , Mary-Ellen Taplin , Geoffrey Shapiro

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT03517969

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 5034)

DOI

10.1200/JCO.2021.39.15_suppl.5034

Abstract #

5034

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Atish Dipankar Choudhury

First Author: Atish Dipankar Choudhury

First Author: Benedito A. Carneiro

First Author: Johann S. De Bono